Mark Lappe

Mark Lappe discloses dealings in 2 companies, chiefly Inhibrx Biosciences, Inc. and Inhibrx, Inc. We count 52 filings; the first trade dates from 28 December 2020 and the latest from 14 October 2026.

In open-market terms, that means 27 purchases worth €6.1M on one side and 17 sales worth €2.7M on the other. Purchases outweigh sales by €3.4M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 3 share grants. Since January 2026: 16 purchases and no sales on the market.

Half of the purchases are above €185k and half below. Relative to company size, the median is 0.016% of market cap (16 purchases with a known value). On 25 out of 27 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 14 October 2026, the filings show an open-market purchase worth €185k in Inhibrx Biosciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.